小分子与α-Synuclein结合的分子基础
Paul Robustelli1,2, Alain Ibanez-de-Opakua3, Cecily Campbell-Bezat1
1D. E. Shaw Research, New York, New York 10036, United States.
Journal of the American Chemical Society
|February 8, 2022
概括
分子动力学模拟揭示了内在无序的蛋白质alpha-synuclein如何与药物fasudil结合. 这种方法可以为与无序蛋白质相关的疾病设计合理的药物.
科学领域:
- 生物化学
- 计算生物学
- 药理学
背景情况:
- 内在无序蛋白质 (IDP) 缺乏稳定的3D结构,使药物设计复杂化.
- 阿尔法同核蛋白聚合与帕金森病有关.
研究的目的:
- 使用分子动力学 (MD) 模拟来理解α-synuclein和药物fasudil之间的原子级相互作用.
- 探索MD模拟用于设计针对境内流离失所者的药物的潜力.
主要方法:
- 单体α-同核素结合法苏迪尔的长时间,原子级MD模拟.
- 将模拟结果与实验性NMR化学转移数据进行比较.
- 用修改的小分子进行进一步的模拟以验证结合预测.
主要成果:
- MD模拟准确地复制了已知的α-synuclein-fasudil结合的NMR数据.
- 在C端附近的充电-充电和π-堆积相互作用之间进行动态穿.
- 随后的NMR实验证实了MD模拟预测的结合亲和性和结构特征.
结论:
- MD模拟提供了原子层面的IDP-连接物相互作用的见解.
- 这种动态穿机制是法苏迪尔结合α-synuclein的关键.
- 基于MD的策略显示出合理的药物设计,
更多相关视频
相关概念视频
Ligand Binding Sites
13.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.9K
Ligand Binding and Linkage
5.0K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.0K
Conserved Binding Sites
4.5K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.5K
Factors Affecting Protein-Drug Binding: Drug-Related Factors
235
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
235
Amyloid Fibrils
10.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.5K
Protein-Drug Binding: Mechanism and Kinetics
1.1K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.1K


